<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02776488</url>
  </required_header>
  <id_info>
    <org_study_id>ELI TBI 1</org_study_id>
    <nct_id>NCT02776488</nct_id>
  </id_info>
  <brief_title>Exogenous Lactate Infusion in Traumatic Brain Injury (ELI-TBI)</brief_title>
  <acronym>ELI-TBI</acronym>
  <official_title>Exogenous Lactate Infusion in TBI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic crisis is a state of energy insufficiency due to impaired mitochondrial function as
      indicated by cerebral microdialysis lactate/pyruvate ratio (LPR). We have performed
      preliminary mechanistic analysis of alternative fuels in humans and have demonstrated proof
      of concept that exogenous fuels alter brain metabolism. We will conduct a multicenter,
      adaptive design-based, proof of concept phase 2 safety study of candidate supplemental fuels
      in patients with severe traumatic brain injury to determine safety and efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic crisis is a state of energy insufficiency due to impaired mitochondrial function as
      indicated by cerebral microdialysis lactate/pyruvate ratio (LPR). We have performed safety
      analysis of exogenous sodium lactate infusions in humans and have demonstrated proof of
      concept that these fuels alter brain metabolism. Animal TBI studies have demonstrated proof
      of concept for exogenous lactate and pyruvate. We will conduct a multicenter, adaptive
      design-based, proof of concept biomarker mechanistic safety study of exogenous sodium
      lactate. The preliminary goal is to determine if exogenous lactate infusion is safe and has a
      demonstrated effect on selected biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Dose ranging and then RCT</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Mortality</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Brain Injuries, Traumatic</condition>
  <arm_group>
    <arm_group_label>ELI Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of exogenous sodium lactate as supplemental fuel within 48 hours of TBI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo infusion of normal saline in Part 2 RCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactate</intervention_name>
    <description>Infusion of exogenous lactate</description>
    <arm_group_label>ELI Arm</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients seen in the Medical Center Emergency Department

          -  Adult patients transferred to the Neurocritical Intensive Care Unit with a physician's
             diagnosis of brain injury.

          -  GCS 3-12

        Exclusion Criteria:

          -  Pregnancy at time of injury

          -  History of diabetes mellitus

          -  History of hemodynamic instability

          -  Known terminal illness which alters brain functioning

          -  Diagnosed AIDS progressed to AIDS dementia

          -  Known history of chronic severe neurological disturbance

          -  Severe retardation

          -  Previous severe diminished mental capacity

          -  No command of either English or Spanish

          -  Arrest for a felony

          -  Active neurologic condition such as stroke, recent TBI

          -  metabolic disorder

          -  preexisting hyperlactatemia

          -  instability precluding experimental intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Vespa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California Los Angeles, Department of Neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Courtney Real, BSN RN</last_name>
    <phone>310-267-7433</phone>
    <email>creal@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David L McArthur, PhD MPH</last_name>
    <phone>310-825-0688</phone>
    <email>dmca@ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Steven Cohen, MHA</last_name>
      <phone>310-794-1801</phone>
      <email>steven.cohen@mednet.ucla.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Glenn TC, Martin NA, Horning MA, McArthur DL, Hovda DA, Vespa P, Brooks GA. Lactate: brain fuel in human traumatic brain injury: a comparison with normal healthy control subjects. J Neurotrauma. 2015 Jun 1;32(11):820-32. doi: 10.1089/neu.2014.3483. Epub 2015 Mar 31.</citation>
    <PMID>25594628</PMID>
  </reference>
  <reference>
    <citation>Glenn TC, Martin NA, McArthur DL, Hovda DA, Vespa P, Johnson ML, Horning MA, Brooks GA. Endogenous Nutritive Support after Traumatic Brain Injury: Peripheral Lactate Production for Glucose Supply via Gluconeogenesis. J Neurotrauma. 2015 Jun 1;32(11):811-9. doi: 10.1089/neu.2014.3482. Epub 2015 Mar 11.</citation>
    <PMID>25279664</PMID>
  </reference>
  <reference>
    <citation>Vespa P, McArthur DL, Stein N, Huang SC, Shao W, Filippou M, Etchepare M, Glenn T, Hovda DA. Tight glycemic control increases metabolic distress in traumatic brain injury: a randomized controlled within-subjects trial. Crit Care Med. 2012 Jun;40(6):1923-9. doi: 10.1097/CCM.0b013e31824e0fcc.</citation>
    <PMID>22610193</PMID>
  </reference>
  <reference>
    <citation>Vespa P, Bergsneider M, Hattori N, Wu HM, Huang SC, Martin NA, Glenn TC, McArthur DL, Hovda DA. Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. J Cereb Blood Flow Metab. 2005 Jun;25(6):763-74.</citation>
    <PMID>15716852</PMID>
  </reference>
  <reference>
    <citation>Vespa P, Tubi M, Claassen J, Buitrago-Blanco M, McArthur D, Velazquez AG, Tu B, Prins M, Nuwer M. Metabolic crisis occurs with seizures and periodic discharges after brain trauma. Ann Neurol. 2016 Apr;79(4):579-90. doi: 10.1002/ana.24606. Epub 2016 Feb 28.</citation>
    <PMID>26814699</PMID>
  </reference>
  <reference>
    <citation>Xu Y, McArthur DL, Alger JR, Etchepare M, Hovda DA, Glenn TC, Huang S, Dinov I, Vespa PM. Early nonischemic oxidative metabolic dysfunction leads to chronic brain atrophy in traumatic brain injury. J Cereb Blood Flow Metab. 2010 Apr;30(4):883-94. doi: 10.1038/jcbfm.2009.263. Epub 2009 Dec 23.</citation>
    <PMID>20029449</PMID>
  </reference>
  <reference>
    <citation>Bouzat P, Magistretti PJ, Oddo M. Hypertonic lactate and the injured brain: facts and the potential for positive clinical implications. Intensive Care Med. 2014 Jun;40(6):920-1. doi: 10.1007/s00134-014-3312-x. Epub 2014 May 1.</citation>
    <PMID>24789621</PMID>
  </reference>
  <reference>
    <citation>Bouzat P, Sala N, Suys T, Zerlauth JB, Marques-Vidal P, Feihl F, Bloch J, Messerer M, Levivier M, Meuli R, Magistretti PJ, Oddo M. Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain. Intensive Care Med. 2014 Mar;40(3):412-21. doi: 10.1007/s00134-013-3203-6. Epub 2014 Jan 30.</citation>
    <PMID>24477453</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 13, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Paul Vespa, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>brain trauma, metabolic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All protected health information (PHI) will be expunged from records before any sharing occurs</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

